Tofersen Linked to Slow but Positive ALS Outcomes Tofersen Linked to Slow but Positive ALS Outcomes
An open-label extension of the phase 3 VALOR trial shows statistically significant benefits for the novel antisense oligonucleotide tofersen in patients with amyotrophic lateral sclerosis.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - June 23, 2022 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
RADICAVA ORS gives people with ALS an oral treatment option that offers the same efficacy as the IV formulation of edaravone1
JERSEY CITY, N.J., June 15, 2022 -- (Healthcare Sales & Marketing Network) -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) to... Biopharmaceuticals, Neurology, Product Launch Mitsubishi Tanabe Pharma, RADICAVA ORS, edaravone, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2022 Category: Pharmaceuticals Source Type: news
Experimental ALS drug OK'd by Health Canada
Health Canada has approved an experimental drug for amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, as uncertainty persists about the drug's clinical benefit. (Source: CBC | Health)
Source: CBC | Health - June 13, 2022 Category: Consumer Health News Tags: News/Health Source Type: news
New ALS Drug Approved in Canada While Still Under FDA Review
MONDAY, June 13, 2022 -- An experimental drug for amyotrophic lateral sclerosis (ALS) was approved in Canada on Monday, but an ongoing evaluation of the treatment by the U.S. Food and Drug Administration has raised questions about its... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 13, 2022 Category: Pharmaceuticals Source Type: news
New Experimental Therapy for A.L.S. Approved in Canada
The F.D.A. is also reviewing the treatment, Albrioza, but the agency ’s scientists have raised questions about its effectiveness. (Source: NYT Health)
Source: NYT Health - June 13, 2022 Category: Consumer Health News Authors: Pam Belluck Tags: Drugs (Pharmaceuticals) Amyotrophic Lateral Sclerosis Clinical Trials Amylyx Pharmaceuticals Inc Food and Drug Administration Canada United States Health Canada your-feed-science Source Type: news
Science Saturday: Link found between key gene and two neurodegenerative diseases
Gene expression can amplify the risk of neurodegenerative diseases for patients, but researchers are still figuring out which genes have an outsized effect on risk and why. In a new paper published in Nature, Mayo Clinic researchers and collaborators have zeroed in on variants of one gene critical for nerve cell function that ups the ante for patients with Lou Gehrig's Disease, also known as amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). "This finding helps clarify a new direction… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 11, 2022 Category: Databases & Libraries Source Type: news
How an Israeli biotech startup is plotting growth in Cambridge
Since its founding in Tel Aviv in 2017, neurodegenerative disease startup NeuroSense Therapeutics has been eyeing the U.S. market. Now, the company (Nasdaq: NRSN) is using its local headquarters in Cambridge to anchor its efforts to advance a drug that aims to treat amyotrophic lateral sclerosis (ALS). (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 31, 2022 Category: Biotechnology Authors: Rowan Walrath Source Type: news
David Niven: 'It was a relief when he died' - star's long battle with Lou Gehrig’s disease
ONCE coined as "Hollywood's ideal Englishman," actor David Niven was best known for his roles as officers, lovers and the iconic James Bond in 1967s Casino Royale. Having been in more than 90 films across his 50 year career, Niven's death in 1983 at the age of 73 was felt by many. Towards the end of his life, the star needed "care 24 hours a day", due to his battle with a disease known as Lou Gehrig's disease or amyotrophic lateral sclerosis . (Source: Daily Express - Health)
Source: Daily Express - Health - May 22, 2022 Category: Consumer Health News Source Type: news
FDA Approves Oral Form of ALS Drug Edaravone FDA Approves Oral Form of ALS Drug Edaravone
The FDA has approved an orally administered version of edaravone for adults with amyotrophic lateral sclerosis.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 13, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Radicava ORS (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
JERSEY CITY, N.J., May 13, 2022 /PRNewswire/ -- Mitsubishi Tanabe Pharma Corporation (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved Radicava ORS (edaravone), the oral form of edaravone, for the treatment... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 13, 2022 Category: Drugs & Pharmacology Source Type: news
FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)
FDA has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). Radicava ORS is an orally administered version of Radicava, which was originally approved in 2017 as an intravenous (IV) infusion to treat ALS, commonly referred to as Lou (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 12, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Ultra-High Dose Drug Slows Functional Decline in Early ALS Ultra-High Dose Drug Slows Functional Decline in Early ALS
An ultra-high dose of methylcobalamin slows functional decline and is safe in patients with early stage amyotrophic lateral sclerosis, results from a new phase 3 study suggest.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - May 12, 2022 Category: Primary Care Tags: Neurology & Neurosurgery News Source Type: news
Alzheimer's disease-related psychosis: an overview of clinical manifestations, pathogenesis, and current treatment - Benmelouka AY, Ouerdane Y, Outani O, Alnasser YT, Alghamdi BS, Perveen A, Ashraf GM, Ebada MA.
Behavioral and psychotic manifestations, including aggression, delusions, and hallucinations, are frequent comorbidities in patients with debilitating nervous illnesses such as Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis, Multiple Sclerosis, an... (Source: SafetyLit)
Source: SafetyLit - April 24, 2022 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
A Biomarker for ALS? A Biomarker for ALS?
A biomarker typically linked with Alzheimer ' s disease may also signal amyotrophic lateral sclerosis.First Look (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - April 21, 2022 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news
Preventing ALS: Insights From Other Neurodegenerative Diseases Preventing ALS: Insights From Other Neurodegenerative Diseases
The authors apply what we know about prodromal clinical markers in other neurodegenerative diseases to amyotrophic lateral sclerosis. Might early therapeutic intervention--or prevention--be possible?Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
